Cargando…
Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Osimertinib (Tagrisso(®)) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mut...
Autor principal: | Scott, Lesley J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300577/ https://www.ncbi.nlm.nih.gov/pubmed/30631243 http://dx.doi.org/10.1007/s40267-018-0536-9 |
Ejemplares similares
-
Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018) -
Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018) -
Anakinra in Still’s disease: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018) -
Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021) -
Daridorexant in Insomnia Disorder: A Profile of Its Use
por: Nie, Tina, et al.
Publicado: (2023)